Remember your first success story with Seretide (salmeterol/fluticasone propionate)

Remember your first success story with Seretide (salmeterol/fluticasone propionate)

Seretide Inhalers

What is Seretide?


Asthma Indication

Seretide is indicated in the regular treatment of asthma where use of a combination product (long- acting β2 agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist1

Or

  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist

Dosing

The recommended dose of Seretide Evohaler 25/50mcg, 25/125mcg or 25/250mcg is two inhalations, twice daily.

Seretide Evohaler comes in three different doses allowing flexibility of dosing for your patient with asthma at low, medium and high dose steroid1.

Inhaler
Save 50%

Seretide Evohaler 25/250mcg
£29.32

Save 23%

Seretide Evohaler 25/125mcg
£23.45

GSK has reduced the list price for Seretide Evohaler 25/125mg and 25/250mcg between August 2018 and December 2018. GSK anticipates that new prices will be reflected in the January 2019 Drug Tariff update4.

What do the list price reductions mean for your patients?

The Seretide Evohaler list price reductions are great news for patients with asthma who prefer a MDI and even better news for those who are already using a Seretide Evohaler.

25/50mcg
120 Doses
25/125mcg
120 Doses
25/250mcg
120 Doses
BTS ICS ClassificationLowMediumHigh
Price£18.00£23.45£29.32
Price ReductionNo change23%50%
£ ReductionNo change£11.55£30.16
Write your next Seretide success story today

Write your next Seretide success story today

Why should you prescribe Seretide?

1

Experience

Seretide has a wealth of patient and physician experience with over 108 million patient treatment years3

2

Efficacy

The original ICS/LABA - Seretide has proven efficacy in Asthma for nearly 20 years2

3

Paediatric Licence

Seretide 25/50 mcg Evohaler is the only MDI licensed in paediatric asthma for children 4 years and upwards, which can be used with both the Volumatic and Aerochamber1

Compare Seretide…
Do you ever prescribe?

Save
versus
Fostair
£

Seretide 25/125mcg is cheaper than Fostair 100/6mcg

At mid dose, Seretide Evohaler 25/125mcg is £5.87 (20%) less expensive than Fostair 100/6 mcg5.

At high dose, Seretide Evohaler 25/250mcg is the same price as Fostair 200/6 mcg at £29.32.

Cost savings are no longer a driver to switch away from Seretide Evohaler to Fostair Inhaler, allowing for choice of inhaler to be based on patient preference.

Seretide is suitable for a greater range of patient needs

compared to Sirdupla...

  • arrowdoes not have a license for paediatric asthma7
  • arrowis not available in a low dose (25/50 mcg) inhaler
  • arrowcannot be used in mild asthma
  • arrowdoes not have the option of three doses therefore patients cannot be stepped down to the lowest dose of ICS as appropriate
  • arrowcontains ethanol and therefore may not be suitable for all patient groups
  • arrowis not licensed for use with a Volumatic spacer
Greater
flexibility
versus
Sirdupla
SAVE £9.53
AT 25/250mcg6

Seretide comes in the Evohaler MDI

The device for patients who prefer an MDI, or when you believe a patient would benefit from an MDI.

Seretide 25/50 mcg Evohaler is the only MDI licensed in paediatric asthma for children 4 years and upwards, which can be used with both the Volumatic and Aerochamber1.

Step 1

Remove the mouthpiece cover and check the mouthpiece inside and outside to see that it is clean and free of objects.

Step 2

Shake the inhaler 4 or 5 times to ensure that any loose objects are removed and that the contents of the inhaler are evenly mixed.

Step 3

Hold the inhaler upright with your thumb on the base, below the mouthpiece. Breathe out as far as is comfortable.

Step 4

Place the mouthpiece in your mouth between your teeth and close your lips firmly around it, do not bite.

Step 5

Breathe in through your mouth, just after starting to breathe in, press firmly down on the top of the cannister to release a puff of medicine. Do this while still breathing in steadily and deeply.

Step 6

Hold your breath, take the inhaler from your mouth and your finger from the top of the Inhaler. Continue holding your breath a few seconds, or as long as comfortable.

Looking to review the effects of the price change in your Local Health Economy (LHE) or manage your rebate?

Value.GSK

Value.GSK

For Commissioners and Payers


Go to Value.GSK

How has the Seretide list price change affected my LHE?

To review the estimated financial savings of the Seretide list price change for your LHE, please visit value.gsk.com

Seretide Rebate

If you have an active Seretide Rebate contract please log into our value.gsk.com site for more information about what the recent Seretide price changes mean to your LHE.

If you are not registered, and you are a NHS medicine manager, respiratory commissioner or in an equivalent role, you can register quickly and easily by visiting value.gsk.com

Free resources to help you and your patients use Seretide Evohaler

Identify patients using the ACT score pad

Identify patients using the ACT score pad

Asthma Control Test (ACT) pad questionnaire to measure the impact of Asthma on a person’s life.

Order now
Ellipta inhalation trainer

Help demonstrate the Evohaler device to patients

Evohaler Demonstration device for healthcare professionals to show patients how to use the Evohaler device correctly.

Order now
Ellipta demonstration device

Teach patients to use the Evohaler device with the Patient Leaflet

How to Use Patient Leaflet pad to teach patients how to use their Evohaler on its own and with a Volumatic Spacer.

Order now

References

  • 1. Seretide SPC. Accessed November 2018
  • 2. Data on File: Seretide Exposure in asthma and COPD June 2017 (RF/SFC/0008/15(3)
  • 3. Seretide Accuhaler SPC - Date of first authorisation: 1 February 1999 (all strengths)
  • 4. DHSC Price Modulation Approval Letter (8-11-18)
  • 5. eMIMS – https://www.mims.co.uk/drugs/respiratory-system/asthma-copd/Fostair (accessed November 2018)
  • 6. eMIMS – https://www.mims.co.uk/drugs/respiratory-system/asthma-copd/sirdupla (accessed November 2018)
  • 7. Sirdupla Inhaler SPC. Accessed November 2018

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Seretide is a registered trademark of the GlaxoSmithKline group of companies

B.A. Last updated: November 2018. UK/SFC/0016/18